Latest Depression News

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.

Richmond Vanadium Technology slows key project activities and reshapes its leadership team to navigate a prolonged period of low vanadium prices while advancing battery technology development.

Bowen Coking Coal has surpassed its full-year 2025 production and sales targets ahead of schedule while transitioning the Burton Mine Complex to an owner-operator model. However, ongoing market challenges and funding uncertainties cast a shadow over its near-term outlook.

Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Cokal Limited has secured US$15 million in strategic debt funding to ramp up metallurgical coal production at its BBM mine, while terminating all agreements with Cratus due to non-performance.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Emyria reports sustained six-month improvements in treatment-resistant PTSD patients and announces a strategic research collaboration with Australian National University to advance mental health care models.

OD6 Metals has secured regulatory approval to launch an 18-hole, 5,000-metre drilling program at its Gulf Creek Copper Project, targeting promising repeat mineral structures. A further 7-hole deep drilling phase awaits approval, potentially expanding exploration near historic high-grade copper zones.

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.

Nufarm reported a mixed 1H25 with a strong rebound in crop protection profits contrasting a sharp decline in seed technologies earnings, prompting a strategic review of the latter business.

Legacy Minerals has lodged an exploration licence application over the Nico Young nickel-cobalt deposit in NSW, securing a nationally significant resource with no acquisition cost. This strategic move positions the company to capitalize on future nickel and cobalt market recoveries.